Immuneering appoints Dr. Igor Matushansky as Chief Medical Officer to enhance clinical development of IMM-1-104 for pancreatic cancer. Immuneering Corporation announced the appointment of Dr. Igor ...

Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with ...

(MENAFN- GlobeNewsWire - Nasdaq) - Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in ...

Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in first-line pancreatic cancer ...

“We were delighted to report updates from our ongoing Phase 2a trial of IMM-1-104 in January 2025 demonstrating excellent response rates for IMM-1-104 in combination with chemotherapy in first ...

Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in first-line pancreatic cancer ...

Dr. Matushansky joins as Immuneering plans to present updated data from Phase 2a trial of IMM-1-104 in pancreatic cancer in Q2 2025 CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Immuneering ...

“We were delighted to report updates from our ongoing Phase 2a trial of IMM-1-104 in January 2025 demonstrating excellent response rates for IMM-1-104 in combination with chemotherapy in first-line ...

"The Phase 2a data we shared in January demonstrates the potential of IMM-1-104 to provide first line pancreatic cancer patients with a new option that is more effective and better tolerated than ...